The overall aim of the 'Improving the Quality of Biomedical Science with 3Rs Concepts' (IMPROVE) COST Action (CA21139) is to establish an interdisciplinary network dedicated to refining, harmonising and promoting the adoption of the Three Rs concepts, to enhance the quality of biomedical research. The 'IMPROVE' COST Action has assembled an Ethics Crossover Group composed of volunteer members from each of IMPROVE's four established Working Groups: 'Quality and translatability of science', 'Implementation', 'Dissemination' and 'Education'. This report relates to a two-day workshop, held in Acibadem University in Istanbul on 2-3 September 2024. The workshop was organised by the Ethics Crossover Group in line with the aims and the scope of the 'IMPROVE' COST Action, to address the ethical dimension of research and experiments on laboratory animals.
{"title":"The Istanbul Workshop organised by the 'IMPROVE' COST Action Ethics Crossover Group.","authors":"Augusto Vitale, Simone Pollo, Nikos Kostomitsopoulos, Aurélie Thomas, Gamze Kaya, Kaan Bicici, Yesim Isil Ulman","doi":"10.1177/02611929251345074","DOIUrl":"https://doi.org/10.1177/02611929251345074","url":null,"abstract":"<p><p>The overall aim of the 'Improving the Quality of Biomedical Science with 3Rs Concepts' (IMPROVE) COST Action (CA21139) is to establish an interdisciplinary network dedicated to refining, harmonising and promoting the adoption of the Three Rs concepts, to enhance the quality of biomedical research. The 'IMPROVE' COST Action has assembled an Ethics Crossover Group composed of volunteer members from each of IMPROVE's four established Working Groups: 'Quality and translatability of science', 'Implementation', 'Dissemination' and 'Education'. This report relates to a two-day workshop, held in Acibadem University in Istanbul on 2-3 September 2024. The workshop was organised by the Ethics Crossover Group in line with the aims and the scope of the 'IMPROVE' COST Action, to address the ethical dimension of research and experiments on laboratory animals.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"53 4","pages":"232-235"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01Epub Date: 2025-06-19DOI: 10.1177/02611929251351559
Alexya Azhakesan, Elena Seiz, Johann Kern, Laura Hendricks, Jens Fleckenstein, Frederic Jungbauer, Sonja Ludwig, Christoph Brochhausen, Luis Bugia, Claudia Scherl, Anne Lammert, Nicole Rotter, Annette Affolter
Patient-derived head and neck squamous cell carcinoma (HNSCC) explant models have been shown to retain the original tumour microenvironment and morphological characteristics. To enhance the human relevance of models and improve clinical outcomes, there is an emerging move toward preclinical models that are cultured in xeno-free media (i.e. media containing no non-human animal-derived components). Fetal bovine serum (FBS) has been the standard cell culture medium supplement in most in vitro systems. However, growing emphasis on ethical concerns, animal welfare considerations and reproducibility, as well as the need to implement the Three Rs principles, have driven substantial efforts to identify viable xeno-free alternatives to FBS. In this study, an ex vivo culture model for HNSCC was developed, based on the use of xeno-free media. Human platelet lysate (hPL)-supplemented medium and a commercially available xeno-free human mesenchymal stromal cell (MSC) expansion medium were evaluated, comparing HNSCC explant model growth to that in the 'standard' FBS-supplemented medium, over a 10-day culture period. To best reflect clinical conditions, the tissues were treated with radiochemotherapy (RCT) comprising cisplatin and fractionated irradiation. After 10 days, the tissues were formalin-fixed, paraffin-embedded, and assessed for the expression of key biomarkers, including PD-L1, Ki-67 and vimentin. The upregulation of PD-L1, as well as the downregulation of Ki-67 and vimentin, were consistent across all media, thus validating hPL-supplemented medium and MSC medium as viable alternatives to FBS-supplemented medium, for use in the culture of humanised HNSCC preclinical models.
{"title":"Xeno-free alternatives to the use of fetal bovine serum in head and neck cancer explant culture.","authors":"Alexya Azhakesan, Elena Seiz, Johann Kern, Laura Hendricks, Jens Fleckenstein, Frederic Jungbauer, Sonja Ludwig, Christoph Brochhausen, Luis Bugia, Claudia Scherl, Anne Lammert, Nicole Rotter, Annette Affolter","doi":"10.1177/02611929251351559","DOIUrl":"10.1177/02611929251351559","url":null,"abstract":"<p><p>Patient-derived head and neck squamous cell carcinoma (HNSCC) explant models have been shown to retain the original tumour microenvironment and morphological characteristics. To enhance the human relevance of models and improve clinical outcomes, there is an emerging move toward preclinical models that are cultured in xeno-free media (i.e. media containing no non-human animal-derived components). Fetal bovine serum (FBS) has been the standard cell culture medium supplement in most <i>in vitro</i> systems. However, growing emphasis on ethical concerns, animal welfare considerations and reproducibility, as well as the need to implement the Three Rs principles, have driven substantial efforts to identify viable xeno-free alternatives to FBS. In this study, an <i>ex vivo</i> culture model for HNSCC was developed, based on the use of xeno-free media. Human platelet lysate (hPL)-supplemented medium and a commercially available xeno-free human mesenchymal stromal cell (MSC) expansion medium were evaluated, comparing HNSCC explant model growth to that in the 'standard' FBS-supplemented medium, over a 10-day culture period. To best reflect clinical conditions, the tissues were treated with radiochemotherapy (RCT) comprising cisplatin and fractionated irradiation. After 10 days, the tissues were formalin-fixed, paraffin-embedded, and assessed for the expression of key biomarkers, including PD-L1, Ki-67 and vimentin. The upregulation of PD-L1, as well as the downregulation of Ki-67 and vimentin, were consistent across all media, thus validating hPL-supplemented medium and MSC medium as viable alternatives to FBS-supplemented medium, for use in the culture of humanised HNSCC preclinical models.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":" ","pages":"188-202"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01Epub Date: 2025-07-07DOI: 10.1177/02611929251350914
{"title":"Spotlight on Three Rs Progress.","authors":"","doi":"10.1177/02611929251350914","DOIUrl":"https://doi.org/10.1177/02611929251350914","url":null,"abstract":"","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"53 4","pages":"181-183"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2025-04-17DOI: 10.1177/02611929251334458
{"title":"Spotlight on Three Rs Progress.","authors":"","doi":"10.1177/02611929251334458","DOIUrl":"https://doi.org/10.1177/02611929251334458","url":null,"abstract":"","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"53 3","pages":"125-126"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2025-04-24DOI: 10.1177/02611929251336678
Judith C Madden
{"title":"Editorial.","authors":"Judith C Madden","doi":"10.1177/02611929251336678","DOIUrl":"https://doi.org/10.1177/02611929251336678","url":null,"abstract":"","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"53 3","pages":"123-124"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2025-04-17DOI: 10.1177/02611929251333981
John Cardone, Achim Knappik
As innovators who made non-animal-derived antibodies available to researchers starting 20 years ago, we have generated more than 60,000 antibodies during this time span. Here, we review and highlight the key challenges that hampered the adoption of research antibodies generated by phage display. We describe the advantages of this method over traditional immunisation-based methods, and provide examples of specific projects. As active participants in attesting the scientific validity of non-animal-derived antibodies, we have contributed and supported key advancements in phage display for the generation of research antibodies. Such advancements have paved the way for the scientific community to switch to animal-free antibodies at a faster pace, as a goal for the near future.
{"title":"20 Years of Providing Custom Non-Animal-Derived Antibodies - A Review.","authors":"John Cardone, Achim Knappik","doi":"10.1177/02611929251333981","DOIUrl":"https://doi.org/10.1177/02611929251333981","url":null,"abstract":"<p><p>As innovators who made non-animal-derived antibodies available to researchers starting 20 years ago, we have generated more than 60,000 antibodies during this time span. Here, we review and highlight the key challenges that hampered the adoption of research antibodies generated by phage display. We describe the advantages of this method over traditional immunisation-based methods, and provide examples of specific projects. As active participants in attesting the scientific validity of non-animal-derived antibodies, we have contributed and supported key advancements in phage display for the generation of research antibodies. Such advancements have paved the way for the scientific community to switch to animal-free antibodies at a faster pace, as a goal for the near future.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"53 3","pages":"168-174"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号